search
Back to results

Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients (GA&COVID19)

Primary Purpose

COVID 19

Status
Unknown status
Phase
Phase 2
Locations
Sudan
Study Type
Interventional
Intervention
Acacia Senegal
Pectin
Sponsored by
Al-Neelain University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COVID 19 focused on measuring Gum Arabic, Immunomodulator

Eligibility Criteria

5 Years - 90 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • COVID 19 infected as proved by real time PCR (polymerase chain reaction) .( newly diagnosed)

Exclusion Criteria:

  • Intubated patients on parental treatment

Sites / Locations

  • Omdurman Teaching Hospital
  • Jabra Hospital,

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Intervention Group

Control group

Arm Description

This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose

This group will be provided with pectin powder provided as one-gram-dose

Outcomes

Primary Outcome Measures

Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )
Changes of the level of Tumor Necrosis Factor (TNF), interleukin IL8,IL6,IL10 from the baseline values
Mortality rate
The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo

Secondary Outcome Measures

Determine viral load in each patient
Change of viral load from Baseline

Full Information

First Posted
May 8, 2020
Last Updated
May 8, 2020
Sponsor
Al-Neelain University
Collaborators
University of Khartoum
search

1. Study Identification

Unique Protocol Identification Number
NCT04381871
Brief Title
Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients
Acronym
GA&COVID19
Official Title
Phase II ,III Randomized Double Blind Parallel Arms Clinical Trial of Potential Role of Gum Arabic ( Acacia Senegal) as Immunomodulatory Agent Among COVID 19 Patients in Sudan
Study Type
Interventional

2. Study Status

Record Verification Date
May 2020
Overall Recruitment Status
Unknown status
Study Start Date
June 1, 2020 (Anticipated)
Primary Completion Date
August 1, 2020 (Anticipated)
Study Completion Date
September 1, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Al-Neelain University
Collaborators
University of Khartoum

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo
Detailed Description
Randomized placebo controlled trial including COVID 19 seropositive patients will be treated with 30 gram per day for 4 weeks, compared to placebo group treated for the same duration in positive COVID 19 patients. Blood samples will be taken first at base line level, after two weeks and after the intervention after satisfying the inclusion and exclusion criteria. The main objective is to assess the effect of Gum Arabic (acacia Senegal) on immune system among COVID-19 patients. The outcome of this project understand SARS-CoV-2 immune response in COVID patients and the effect of Gum Arabic (Acacia Senegal) consumption to counteract progression of the disease

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID 19
Keywords
Gum Arabic, Immunomodulator

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
110 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention Group
Arm Type
Experimental
Arm Description
This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
This group will be provided with pectin powder provided as one-gram-dose
Intervention Type
Dietary Supplement
Intervention Name(s)
Acacia Senegal
Other Intervention Name(s)
Gum Arabic
Intervention Description
Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Pectin
Intervention Description
Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
Primary Outcome Measure Information:
Title
Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )
Description
Changes of the level of Tumor Necrosis Factor (TNF), interleukin IL8,IL6,IL10 from the baseline values
Time Frame
4 weeks
Title
Mortality rate
Description
The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo
Time Frame
from the date of assignment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to two months
Secondary Outcome Measure Information:
Title
Determine viral load in each patient
Description
Change of viral load from Baseline
Time Frame
4 weeks
Other Pre-specified Outcome Measures:
Title
clinical improvement and hospital discharge
Description
Time of discharge from hospital after full recovery
Time Frame
from the date of assignment until the date of hospital discharge for the last assigned case, whichever comes first, assessed up to two months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: COVID 19 infected as proved by real time PCR (polymerase chain reaction) .( newly diagnosed) Exclusion Criteria: Intubated patients on parental treatment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dr Babiker, PhD
Phone
+249912951517
Email
rashat33@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Shahenaz Satti, MSc
Phone
+249912204825
Email
shahenazsatti@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mustafa KM Nimeiri, MD
Organizational Affiliation
Al Neelain University, Faculty of Medicine
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Moawia M Mukhtar, PhD
Organizational Affiliation
University of Khartom , Institute of Endemic Diseases
Official's Role
Study Director
Facility Information:
Facility Name
Omdurman Teaching Hospital
City
Khartoum
State/Province
Omdurman
Country
Sudan
Facility Name
Jabra Hospital,
City
Khartoum
Country
Sudan

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32328307
Citation
Ali NE, Kaddam LA, Alkarib SY, Kaballo BG, Khalid SA, Higawee A, AbdElhabib A, AlaaAldeen A, Phillips AO, Saeed AM. Gum Arabic (Acacia Senegal) Augmented Total Antioxidant Capacity and Reduced C-Reactive Protein among Haemodialysis Patients in Phase II Trial. Int J Nephrol. 2020 Apr 9;2020:7214673. doi: 10.1155/2020/7214673. eCollection 2020.
Results Reference
background
PubMed Identifier
30112005
Citation
Kamal E, Kaddam LA, Dahawi M, Osman M, Salih MA, Alagib A, Saeed A. Gum Arabic Fibers Decreased Inflammatory Markers and Disease Severity Score among Rheumatoid Arthritis Patients, Phase II Trial. Int J Rheumatol. 2018 Jul 5;2018:4197537. doi: 10.1155/2018/4197537. eCollection 2018.
Results Reference
background
PubMed Identifier
32287140
Citation
Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-773. doi: 10.14309/ajg.0000000000000620.
Results Reference
background
PubMed Identifier
32376400
Citation
Ruscitti P, Berardicurti O, Iagnocco A, Giacomelli R. Cytokine storm syndrome in severe COVID-19. Autoimmun Rev. 2020 Jul;19(7):102562. doi: 10.1016/j.autrev.2020.102562. Epub 2020 May 3. No abstract available.
Results Reference
background
PubMed Identifier
32891160
Citation
Kaddam L, Babiker R, Ali S, Satti S, Ali N, Elamin M, Mukhtar M, Elnimeiri M, Saeed A. Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients: A structured summary of a protocol for a randomised, controlled, clinical trial. Trials. 2020 Sep 5;21(1):766. doi: 10.1186/s13063-020-04707-2.
Results Reference
derived

Learn more about this trial

Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients

We'll reach out to this number within 24 hrs